This episode examines two FDA-cleared AI systems for pulmonary nodule detection and characterization—eyonis LCS from Median Technologies and RevealAI-Lung from RevealDx—both cleared within one week and both reimbursable under Medicare Category III CPT codes. The briefing covers clinical performance benchmarks including sensitivity, specificity, and negative predictive value, the validation frameworks used in pivotal trials and multi-cohort studies, and the reimbursement infrastructure enabling immediate deployment. The episode concludes with UV Smart Technologies’ clearance of the D sixty UV-C disinfection system for cardiac probes, representing a shift from two-hour chemical processes to two-minute automated cycles in medical device reprocessing.
